ClinConnect ClinConnect Logo
Search / Trial NCT03050671

Effects of External Leg Compression Devices on Healing and Blood Clotting

Launched by KAROLINSKA UNIVERSITY HOSPITAL · Feb 9, 2017

Trial Information

Current as of November 07, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

This small study is testing two calf compression devices that squeeze the leg to improve blood flow and help prevent clots. It uses a crossover design, meaning each participant will try both devices in separate periods. One device gives rapid, sharp squeezes (Rapid calf-IPC) and the other provides gentler, slower squeezes (Slow calf-IPC). Each device is worn on both calves for about 120 minutes while researchers measure blood clotting factors in the blood, and also look at how the tissue in the Achilles area metabolizes, how much collagen is produced, and how well the leg’s microcirculation is working.

Who can participate? The study is for healthy adult men ages 18–60 who are non-smokers and have no major heart or kidney disease or past surgeries that affect leg blood flow. It’s being conducted at Karolinska University Hospital in Stockholm, Sweden. About 10 participants are planned, and enrollment is currently by invitation. There are no results yet, but the researchers hope to learn which device pattern might better support blood flow and healing, with possible implications for how compression devices are used in the future.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Healthy individuals
  • Male gender
  • Age 18-60
  • Exclusion Criteria:
  • Smoking
  • Severe cardiovascular or renal disease causing pitting oedema
  • Previous operation in the lower limbs affecting the vascular or lymphatic system

About Karolinska University Hospital

Karolinska University Hospital is a leading academic medical center in Sweden, renowned for its commitment to advanced healthcare research and innovative clinical practices. As a key sponsor of clinical trials, the hospital leverages its extensive expertise in medical research and collaboration with Karolinska Institutet, one of the world's foremost medical universities. The institution is dedicated to enhancing patient care through rigorous scientific investigation, focusing on a wide range of therapeutic areas. With a multidisciplinary approach and a strong emphasis on translational medicine, Karolinska University Hospital aims to bridge the gap between laboratory findings and clinical application, ultimately striving to improve health outcomes and advance medical knowledge.

Locations

Stockholm, Sweden

Patients applied

0 patients applied

Trial Officials

Paul Ackermann

Principal Investigator

Karolinska University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials